Primary lymphoma of the liver:  
A case report and review

Franzjosef Schweiger MD FRCPC FACP FACG, Rowen Shinder MD FRCPC, Sheldon Rubin MD FRCPC

Liver involvement in non-Hodgkin’s lymphoma is common and occurs in more than 50% of patients (1,2). However, primary hepatic lymphoma (PHL) is rare in the absence of systemic involvement, and fewer than a hundred such patients have been described in the literature. Most cases before 1980 were reported in autopsy studies, but in the past two decades, diagnostic imaging and tissue sampling suggest an increasing frequency of this tumour, especially in the setting of immunosuppression (3-8).

We report a case of PHL in a previously healthy patient and briefly review the literature on this topic.

**CASE PRESENTATION**

A 40-year-old, previously healthy, white man presented with a 10-week history of generalized malaise, anorexia, nausea, epigastric pain and weight loss of 7 kg. The pain was persistent, radiating into the back, worse postprandially and, at times, awakening him at night. He found no relief with a histamine2-receptor antagonist. He denied intake of other medications or alcohol, but smoked 20 cigarettes/day. There was no history of fever, night sweats or jaundice, and he had no risk factors for viral hepatitis. On admission to hospital, the physical examination revealed epigastric tenderness but no palpable mass, lymphadenopathy, hepatosplenomegaly or peripheral stigmata of chronic liver disease.

Initial laboratory studies showed normal complete blood counts, and normal bilirubin and transaminase levels. The serum alkaline phosphatase level was mildly elevated at 150 U/L (normal is 39 to 117 U/L) as was the lactate dehydrogenase level at 255 U/L (normal is 70 to 242 U/L). The level of C-reactive protein was 92 mg/L (normal is 0 to 10 mg/L). Serum carcinoembryonic antigen and alpha-fetoprotein levels were normal. Serological tests for the hepatitis B virus, hepatitis C virus (HCV), Epstein-Barr virus and human immunodeficiency virus were negative.

A computed tomography (CT) scan of the abdomen demonstrated a mass approximately 10 cm in diameter, involving the caudate and part of the right lobe of the liver (Figure 1). It was of decreased attenuation compared with the surrounding liver, and its contour was ill defined. There was no intra-abdominal lymphadenopathy. Other imaging studies included CT scans of the chest and neck, a small bowel follow-through, and a bone scan, all of which were normal. A gallium scan showed increased uptake of isotope within the upper portion of the central abdomen corresponding to the liver mass. An endoscopy was unremarkable.
Histological examination of the liver biopsy specimens obtained by needle aspiration under CT guidance revealed a diffuse large cell type of non-Hodgkin’s lymphoma (Figure 2). Tumour cells were positive for leukocyte common antigen and UCHL-1, and were focally positive for CD-3 and MT1. The cells were negative for epithelial membrane antigen, cytokeratin and alpha-fetoprotein, suggesting that the neoplasm was of T-cell origin. Bone marrow aspiration and biopsy did not show any involvement by the lymphoma.

The patient initially was treated with four courses of cyclophosphamide, doxorubicin, vincristine and prednisone, but improved only temporarily. A repeat evaluation by CT scan five months after his initial admission revealed progression of the tumour, and despite further aggressive chemotherapy, he developed profound jaundice, ascites and renal failure, and died two months later.

DISCUSSION

First described in 1965 by Ata and Kamel (9), PHL is not a common hepatic neoplasm. It frequently occurs in the fourth decade of life, with a four to one male preponderance (6). Abdominal pain, hepatomegaly, fever, night sweats and weight loss are the presenting clinical features in the vast majority of patients (6) but are nonspecific. Hepatocellular carcinoma, a much more common liver neoplasm, often presents in the same manner. Unusual presentations of PHL include jaundice and ascites (7), thrombocytopenia (10,11), hypercalcemia (12) and acute fulminant hepatic failure (13).

In the past decade, an increasing number of cases of PHL have occurred in immunocompromised patients, particularly in those with the human immunodeficiency virus (8,14).

Laboratory investigations typically show an elevated lactate dehydrogenase level, and normal or mildly abnormal serum alkaline phosphatase and transaminase levels; however, tests are typically negative for conventional tumour markers such as carcinoembryonic antigen and alpha-fetoprotein (3,5).

In most cases, the lymphoma is evident on imaging studies as a solitary mass in the liver, although multiple discrete lesions have also been described, especially in immunosuppressed patients (8,15). Rarely is there diffuse infiltration of the liver by the tumour (3,4,6,13). Although there is not a single characteristic imaging finding of PHL, a homogeneous hypoechoic lesion on ultrasonography combined with a solid low attenuation defect on a CT scan is very suggestive of PHL (15). A definitive diagnosis can be reached only by examination of histological material obtained either by percutaneous biopsy or laparotomy.

Most reported lesions are large cell lymphomas, and immunohistochemical analysis is necessary to distinguish these tumours from poorly differentiated carcinomas. In the patient described in this report, the abnormal cells stained positively for leukocyte common antigen and negative for epithelial markers, confirming the diagnosis of lymphoma. Immunophenotyping suggested that the tumour was of T-cell origin. In the literature, about 80% of PHLs are B-cell tumours, whereas the T-cell phenotype accounts for only 8% to 28% of cases (11,16).

The pathogenesis of PHL remains unknown. Previous observations point toward underlying immune abnormalities in some patients. Thus, PHL has been associated with systemic lupus erythematosus (17), Felty’s syndrome (18), primary biliary cirrhosis (19-21), organ transplantation and chemical immunosuppression (22). In addition, 15 cases of PHL in patients infected with the human immunodeficiency virus have been reviewed (8).

Chronic antigenic stimulation by viruses could be another mechanism of lymphomagenesis. Several cases of PHL in hepatitis B virus-infected patients have been described,
(11,16,23-26), but the virus has not been demonstrated in neoplastic cells per se (24,25).

HCV, another hepatotropic virus causing chronic liver disease, has been isolated from lymphocytes and lymphoid tissue (26,27), and recently has been linked to non-Hodgkin’s lymphoma in some, but not all, studies (28-31). Several cases of PHL associated with HCV infection have been reported (32-38). Using in situ hybridization, the HCV genome was detected recently in lymphoma cells of a patient with PHL, raising the possibility of direct oncogenic potential (38). Clearly, further investigations are needed to clarify the role of this virus in PHL. The patient described in this report had no serological markers for these viruses.

The optimal therapy for PHL remains unknown. In localized and respectable tumours, good long term results have been achieved with surgical extirpation alone or combined with chemotherapy (3,5,6,39-41). Multiagent chemotherapy alone seems more appropriate in cases of diffuse infiltration and has led to prolonged remissions in some cases (3-6). Conversely, prognosis and response to treatment are poor in patients with extensive disease, coexisting liver disease or acquired immunodeficiency syndrome (7). REFERENCES


